Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Readmission rates and outcomes in adults with and without COVID-19 following inpatient chemotherapy admission: A nationwide analysis
Philip Kanemo, Keffi Mubarak Musa, Vaishali Deenadayalan, Rafaella Litvin, Olubunmi Emmanuel Odeyemi, Abdultawab Shaka, Naveen Baskaran, Hafeez Shaka
Philip Kanemo, Department of Internal Medicine, Rapides Regional Medical Center, Alexandria, LA 71301, United States
Keffi Mubarak Musa, Department of Medicine, Ahmadu Bello University Teaching Hospital, Zaria 88445, Kaduna, Nigeria
Vaishali Deenadayalan, Rafaella Litvin, Hafeez Shaka, Department of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL 60623, United States
Olubunmi Emmanuel Odeyemi, Department of Internal Medicine, Ladoke Akintola University Teaching Hospital, Ogbomoso 210101, Oyo, Nigeria
Abdultawab Shaka, Department of Medicine, Windsor University School of Medicine, St. Kitts, Frankfort, IL 60423, United States
Naveen Baskaran, Department of Medicine, University of Florida, Gainesville, FL 32610, United States
Author contributions: Kanemo P and Shaka H conceived of the presented idea and designed and proposed the study protocol; Deenadayalan V and Litvin R extracted data from the nationwide readmission database; Shaka A and Baskaran N provided tools for analysis and conducted the analysis; Musa KM, Shaka H and Odeyemi OE interpreted the analysis results and wrote the manuscript; Shaka H and Kanemo P supervised the findings of this work; all authors discussed the results and contributed to the final manuscript.
Institutional review board statement: As the nationwide readmission database data is anonymous and cannot be used to identify patients, institutional review board approval was not required for this study.
Informed consent statement: As the nationwide readmission database data is anonymous and cannot be used to identify patients, informed consent statement was not required for this study.
Conflict-of-interest statement: The authors hereby declare no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Keffi Mubarak Musa, MBBS, Doctor, Research Assistant, Department of Medicine, Ahmadu Bello University Teaching Hospital, Flat 8, street A, Transit Camp, Shika, Zaria 88445, Kaduna, Nigeria. keffimubarakmusa@gmail.com
Received: May 7, 2023
Peer-review started: May 7, 2023
First decision: July 4, 2023
Revised: July 12, 2023
Accepted: August 8, 2023
Article in press: August 8, 2023
Published online: August 24, 2023
ARTICLE HIGHLIGHTS
Research background
The coronavirus disease 2019 (COVID-19) pandemic has had a profound impact on healthcare services and has resulted in modifications to the management of various diseases.
Research motivation
The treatment of cancer has undergone significant changes during the COVID-19 pandemic. Understanding the effects of these changes can provide valuable insights to better prepare for future pandemics.
Research objectives
This study aims to provide insights into the outcomes of hospitalization for in hospital chemotherapy during the COVID-19 pandemic.
Research methods
We conducted a retrospective review of a Nationwide Readmission Database for patients undergoing inpatient chemotherapy (IPCT) during the COVID-19 pandemic. We analyzed data on readmission rates, causes of readmission, and predictors of readmission.
Research results
We found a 90-day readmission rate of 59.8% and a 30-day readmission rate of 73.93%. The most common cause of readmission was chemotherapy encounters (66.7%). Predictors of readmission included peripheral vascular disorders [Hazard ratio (HR) = 1.09, P = 0.04] and paralysis (HR = 1.26, P < 0.001). The total cost incurred due to readmission during the pandemic was 1193000000.00 dollars.
Research conclusions
The COVID-19 pandemic has had a significant impact on the management of cancer patients. There is a need for a more strategic approach to the care of patients undergoing IPCT during pandemics.
Research perspectives
This study opens the door for further investigation into the effects of pandemics on disease management.
